Page last updated: 2024-12-11

2-(3,5-dimethyl-1H-pyrrol-2-yl)-1,3-benzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

## 2-(3,5-dimethyl-1H-pyrrol-2-yl)-1,3-benzothiazole: A Promising Molecule

**2-(3,5-dimethyl-1H-pyrrol-2-yl)-1,3-benzothiazole** is an organic compound with a complex molecular structure. It consists of a benzothiazole ring fused to a pyrrole ring, with two methyl groups attached to the pyrrole ring.

**Its importance in research stems from its potential applications in various fields, including:**

* **Organic Electronics:** This molecule exhibits strong fluorescence properties, making it a candidate for use in organic light-emitting diodes (OLEDs) and other organic electronics. Its structure suggests potential for tunable optoelectronic properties, allowing for fine-tuning of its characteristics for specific applications.
* **Materials Science:** The rigid and planar structure of the molecule makes it suitable for building functional materials, potentially including thin films and supramolecular assemblies. Its fluorescent properties could be exploited for creating self-assembled materials with specific optical functionalities.
* **Biomedical Research:** The unique structure of the compound may hold potential for development of new drugs or probes for biological imaging and diagnostics. For example, its fluorescence properties could be used to track biological processes or identify specific targets within cells.

**Key Research Areas:**

* **Synthesis and Characterization:** Scientists are actively developing efficient synthesis methods for this molecule and investigating its physical and chemical properties, including its optical properties, thermal stability, and electrochemical behavior.
* **Structure-Property Relationships:** Research is being conducted to understand how modifications to the molecular structure of the compound affect its properties. This knowledge is crucial for designing new derivatives with enhanced or tailored functionalities.
* **Applications Development:** Researchers are exploring the potential applications of the compound in various fields, including organic electronics, materials science, and biomedical research.

**Overall, 2-(3,5-dimethyl-1H-pyrrol-2-yl)-1,3-benzothiazole represents a promising molecule with significant potential for advancement in various research areas. Further research is required to fully understand its properties and unlock its full potential for practical applications.**

Cross-References

ID SourceID
PubMed CID9115581
CHEMBL ID1482571
CHEBI ID121671

Synonyms (11)

Synonym
smr000595801
MLS001177330
CHEBI:121671
HMS2897F06
2-(3,5-dimethyl-1h-pyrrol-2-yl)-1,3-benzothiazole
CHEMBL1482571
Q27210234
Z169851642
AKOS033555693
DTXSID101321640
877973-32-5
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzothiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (16)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, Ferritin light chainEquus caballus (horse)Potency50.11875.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency4.77550.007215.758889.3584AID588342
acid sphingomyelinaseHomo sapiens (human)Potency12.589314.125424.061339.8107AID504937
thioredoxin reductaseRattus norvegicus (Norway rat)Potency28.18380.100020.879379.4328AID588453
ATAD5 protein, partialHomo sapiens (human)Potency15.66940.004110.890331.5287AID504466; AID504467
TDP1 proteinHomo sapiens (human)Potency16.36010.000811.382244.6684AID686978
67.9K proteinVaccinia virusPotency10.00000.00018.4406100.0000AID720579
glucocerebrosidaseHomo sapiens (human)Potency28.18380.01268.156944.6684AID2101
P53Homo sapiens (human)Potency56.23410.07319.685831.6228AID504706
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency50.11870.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency9.20000.00419.984825.9290AID504444
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
nuclear receptor ROR-gamma isoform 1Mus musculus (house mouse)Potency3.16230.00798.23321,122.0200AID2546
gemininHomo sapiens (human)Potency0.00520.004611.374133.4983AID624297
VprHuman immunodeficiency virus 1Potency63.09571.584919.626463.0957AID651644
muscleblind-like protein 1 isoform 1Homo sapiens (human)Potency39.81070.00419.962528.1838AID2675
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]